Breakout Stocks
SRZN is part of our breakout stocks list, indicating it is showing strong recent technical strength.
SURROZEN INC (SRZN) Stock Price & Overview
NASDAQ:SRZN • US86889P2083
Current stock price
29.86 USD
+1.66 (+5.89%)
Last:
The current stock price of SRZN is 29.86 USD. Today SRZN is up by 5.89%. In the past month the price increased by 18.45%. In the past year, price increased by 206.35%.
SRZN Key Statistics
52-Week Range5.9 - 30.49
Current SRZN stock price positioned within its 52-week range.
1-Month Range23.63 - 30.49
Current SRZN stock price positioned within its 1-month range.
- Market Cap
- 343.091M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -15.32
- Dividend Yield
- N/A
SRZN Stock Performance
Today
+5.89%
1 Week
+8.98%
1 Month
+18.45%
3 Months
+49.30%
Longer-term
6 Months +119.88%
1 Year +206.35%
2 Years +177.51%
3 Years +223.69%
5 Years N/A
10 Years N/A
SRZN Stock Chart
SRZN Stock Screens
SRZN currently appears in the following ChartMill screener lists.
SRZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRZN. When comparing the yearly performance of all stocks, SRZN is one of the better performing stocks in the market, outperforming 97.09% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SRZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRZN. The financial health of SRZN is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SRZN Earnings
Next Earnings DateMay 8, 2026
Last Earnings DateMar 23, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported528K
EPS Surprise %
Revenue Surprise -21.69%
SRZN Forecast & Estimates
10 analysts have analysed SRZN and the average price target is 39.53 USD. This implies a price increase of 32.37% is expected in the next year compared to the current price of 29.86.
For the next year, analysts expect an EPS growth of 37.58% and a revenue growth -28.12% for SRZN
Analysts
Analysts84
Price Target39.53 (32.38%)
EPS Next Y37.58%
Revenue Next Year-28.12%
SRZN Groups
Sector & Classification
SRZN Financial Highlights
Over the last trailing twelve months SRZN reported a non-GAAP Earnings per Share(EPS) of -15.32. The EPS increased by 28.28% compared to the year before.
Income Statements
Revenue(TTM)3.48M
Net Income(TTM)-242.03M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -245.15% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-133.1%
Sales Q2Q%-19.39%
EPS 1Y (TTM)28.28%
Revenue 1Y (TTM)-67.37%
SRZN Ownership
Ownership
Inst Owners94.33%
Shares11.49M
Float11.13M
Ins Owners0.44%
Short Float %3.97%
Short Ratio2.95
SRZN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SRZN
Company Profile
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Company Info
IPO: 2020-11-23
SURROZEN INC
171 Oyster Point Blvd, Suite 400
South San Francisco CALIFORNIA US
CEO: Gad Soffer
Employees: 40
Phone: 16504752820
SURROZEN INC / SRZN FAQ
What does SURROZEN INC do?
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
What is the stock price of SURROZEN INC today?
The current stock price of SRZN is 29.86 USD. The price increased by 5.89% in the last trading session.
Does SRZN stock pay dividends?
SRZN does not pay a dividend.
What is the ChartMill rating of SURROZEN INC stock?
SRZN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does SURROZEN INC belong to?
SURROZEN INC (SRZN) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of SURROZEN INC (SRZN) based on its PE ratio?
SURROZEN INC (SRZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.32).
Should I buy SRZN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SRZN.